Pharma News
28 Sep 2025 to 04 Oct 2025
Oct 4, 2025
For the first time, Colorado is setting its own limits on medication costs - The Washington Post
Colorado regulators have approved a price cap on Amgen's Enbrel, reducing its cost to $2,355 for a 30-day supply, down from $7,402. This move aims to address rising prescription drug prices, following similar actions in Maryland, Minnesota, and Washington. The pharmaceutical industry, including Amgen, opposes the cap, citing potential access barriers and impacts on innovation.
Oct 4, 2025
CDSCO Initiates Risk-Based Inspections in Six States Following Child Fatalities Associated with ...
The Central Drugs Standard Control Organisation (CDSCO) has initiated risk-based inspections at pharmaceutical manufacturing sites in six states following child deaths in Madhya Pradesh linked to contaminated cough syrup. This move aims to enhance safety and regulatory compliance in the industry.
Oct 4, 2025
Costco to provide significant price reductions on Ozempic and Wegovy for uninsured members.
Costco has partnered with Novo Nordisk to offer weight-loss medications Ozempic and Wegovy at discounted prices for members without insurance, starting October 3rd. A four-week supply will cost $499 at over 600 Costco pharmacies. Both drugs contain semaglutide, aiding in appetite control and blood sugar management, but may have side effects. Demand for these medications has surged amid rising obesity rates in the U.S.
Oct 4, 2025
Rajasthan Health Minister makes significant remarks regarding the cough syrup incident, according to Drugs Control Media Services.
Rajasthan Health Minister addressed the cough syrup case linked to child deaths, stating it was a family mistake and denying any involvement from the health department. The controversy also highlights issues regarding the distribution of banned drugs by the Health Department.
Oct 3, 2025
European physicians recommend GLP-1 medications as the primary choice for obesity treatment - India Today
The European Association for the Study of Obesity recommends Novo Nordisk's semaglutide (Wegovy, Ozempic) and Eli Lilly's tirzepatide (Zepbound, Mounjaro) as first-line treatments for obesity. The guidelines emphasize their effectiveness in weight loss and managing obesity-related complications, while also acknowledging the need for comprehensive patient care and lifestyle strategies.
Oct 3, 2025
MRK Shares Rise Almost 14% This Week: What’s Behind the Surge? - The Globe and Mail
Shares of Merck (MRK) surged nearly 14% this week, driven by optimism in the pharmaceutical sector following Pfizer's (PFE) landmark deal with the Trump administration to reduce drug costs and boost U.S. manufacturing. The deal alleviates concerns over tariffs and pricing, benefiting other drugmakers like AstraZeneca (AZN) and Eli Lilly (LLY), which also saw stock gains.
Oct 3, 2025
CMS Implements Enhanced Safeguards for Orphan Drugs in Response to IRA Price Negotiations
The U.S. Centers for Medicare and Medicaid Services has finalized guidelines for the Inflation Reduction Act’s drug price negotiation program, exempting orphan drugs from negotiations. Experts warn this could delay savings on expensive drugs like Keytruda and Opdivo. The second cycle of negotiations includes Novo Nordisk’s Ozempic and Rybelsus, with final prices due by November 30.
Oct 3, 2025
Pharmaceutical Excipients Forecast for 2025–2032: Projected Robust CAGR of 8.4% Reaching USD 19.29...
The Global Pharmaceutical Excipients Market is projected to grow from USD 10.96 billion in 2025 to USD 19.29 billion by 2032, with a CAGR of 8.4%. Key drivers include rising demand for generic drugs and chronic disease prevalence. North America will dominate the market, while trends towards natural excipients and innovations in drug delivery systems are expected to enhance growth.
Oct 3, 2025
Costco ignites excitement with half-off Ozempic sales | Daily Mail Online
Novo Nordisk's weight loss drugs, Ozempic and Wegovy, will be available at Costco pharmacies for $499 per month. This partnership aims to provide affordable access to these medications, which contain semaglutide. However, users report severe side effects, including gastroparesis, leading to lawsuits against Novo Nordisk. The drugs are effective for weight loss but come with significant health risks.
Oct 3, 2025
Devastating Cough Syrup Situation: Rajasthan Protects Producer Despite Child Fatalities, While ...
At least nine children have died in India due to suspected contaminated cough syrups, prompting investigations into the crisis. Rajasthan is reportedly shielding the manufacturer, while Chhindwara's Collector attributes the deaths to adulteration. The situation highlights serious concerns over pharmaceutical safety and regulatory oversight in the country.
Oct 3, 2025
Esperion rises following patent victory against Dr. Reddy's cholesterol medications — TradingView News
Shares of Esperion (ESPR) rose 6.5% to $3.09 following a settlement with Dr. Reddy’s Laboratories, preventing the sale of generic versions of its cholesterol drugs Nexletol and Nexlizet in the U.S. until April 2040. This deal resolves a patent lawsuit and follows similar settlements with Micro Labs, Hetero USA, and Accord Healthcare.
Oct 3, 2025
DCGI instructs Chennai CDSCO to promptly inspect Coldrif cough syrup manufacturing facility.
The Drug Controller General of India (DCGI) has instructed the Chennai CDSCO to conduct an immediate inspection of the Coldrif cough syrup plant in Kancheepuram, following reports of contamination linked to the syrup in Madhya Pradesh and Rajasthan.
Oct 3, 2025
Promoting Pharmaceutical Products from Bangladesh - Dhaka - The Financial Express
At a recent conference in Dhaka organized by Square Pharmaceuticals, industry leaders highlighted the growth of Bangladesh's pharmaceutical sector, which is expanding at 15% annually. They urged improvements in quality standards and government support for testing facilities. Companies like Square, Incepta, and Beximco are pivotal in meeting local demand and exporting medicines, with a call for liberalized patent regulations to enhance global competitiveness.
Oct 3, 2025
FDA Introduces Accelerated Review Initiative for Generic Medications Utilizing US-Sourced Ingredients
The FDA has launched a fast-track review program for generic drugs made entirely with U.S.-sourced materials, aiming to expedite their market entry. This initiative prioritizes applications that meet strict domestic production criteria, enhancing domestic pharmaceutical manufacturing and reducing foreign supply chain reliance. Specific timelines for the expedited reviews have yet to be announced.
Oct 3, 2025
Wockhardt seeks approval from the USFDA for its 'miracle' antibiotic, Zaynich - TradingView
Wockhardt has submitted a New Drug Application (NDA) to the USFDA for its novel antibiotic Zaynich, targeting complicated urinary tract infections caused by multi-drug resistant bacteria. Zaynich, a combination of Zidebactam and Cefepime, showed a 96.8% cure rate in trials. If approved, it could tap into a $7 billion market, marking a significant milestone for Indian pharma innovation.
Oct 2, 2025
Establishing a local market for cutting-edge medications via private health insurance.
China has introduced a draft Commercial Insurance Innovative Drug List, featuring 121 drugs for price negotiations, aiming to enhance its domestic pharmaceutical market. Notable inclusions are Semaglutide (Novo Nordisk), Opdivo (Bristol Myers), and Tecentriq (Roche). However, high-cost treatments like Cejemly and Tai’ai remain uninsured, highlighting challenges in balancing local and foreign drug interests.
Oct 2, 2025
Delhi High Court Rules Police Lacks Authority to File FIRs for Violations of Drugs and Cosmetics Act
The Delhi High Court ruled that the police lack jurisdiction to register FIRs for offences under the Drugs and Cosmetics Act, 1940. Such actions can only be initiated by a competent officer, clarifying the enforcement framework for drug-related offences.
Oct 2, 2025
Judge Known for Strong Anti-Abortion Stance Withdraws from Major Mifepristone Case
A Texas federal judge, Matthew Kacsmaryk, has transferred the case regarding the abortion drug mifepristone from his court to a Missouri federal court, where it will be decided if the case can continue. This follows a Supreme Court ruling that the original plaintiffs lacked standing. The Missouri Attorney General's office aims to hold the FDA accountable for its regulations on mifepristone.
Oct 2, 2025
Legal Measures to be Taken Against Inferior Medications: HM Prakash Abitkar, DrugsControl Media Services
The Maharashtra State Health Department is set to establish a flying squad to conduct surprise inspections at government hospitals to combat the distribution of duplicate and substandard medicines. Legal action will follow against those found supplying such drugs, as announced by Health Minister Prakash Abitkar.
Oct 2, 2025
Will Galafold Propel Amicus' Expansion Through the End of 2025? - TradingView
Amicus Therapeutics' lead product, Galafold (migalastat), continues to drive the company's revenue, generating $233.1 million in the first half of 2025, an 11% increase year-over-year. The drug is protected by patents until 2038. Amicus also reported strong sales for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), but remains vulnerable to competition from companies like Sanofi and Takeda.
Oct 2, 2025
FDA Greenlights New Generic Form of Mifepristone Abortion Medication Despite Ongoing Debate
The FDA has approved a new generic version of the abortion pill mifepristone, produced by Evita Solutions, sparking backlash from anti-abortion advocates and Trump administration figures. Critics, including Sen. Josh Hawley, have expressed concerns over the FDA's leadership and called for a reassessment of the drug's safety amid ongoing legal challenges and state restrictions on abortion access.
Oct 2, 2025
The launch of Novo Nordisk's highly anticipated drug Ozempic in India is approaching, along with the arrival of its generic alternatives.
Novo Nordisk has received approval from India's CDSCO to sell its diabetes medication Semaglutide, branded as Ozempic. This once-weekly injection, which generated $17 billion in global sales in 2024, will soon be available alongside other Semaglutide products. As the patent expires in early 2026, Indian generic companies like Sun Pharma and Dr Reddy's are preparing to launch their versions.
Oct 2, 2025
Ozempic Approved in India: Key Information to Consider Before Using Hollywood's Popular Weight-Loss Medication
Novo Nordisk's Ozempic, a semaglutide injection, has been approved in India for adults with type 2 diabetes. Known for its weight-loss benefits, Ozempic helps manage blood sugar and may reduce cardiovascular risks. However, it carries potential side effects, necessitating medical supervision. The drug's affordability and access will determine its impact on Indian patients, with prices expected to align with similar therapies.
Oct 2, 2025
European physicians recommend that Novo and Lilly's weight-loss medications be prioritized as the initial treatment for obesity.
Novo Nordisk's semaglutide (Wegovy, Ozempic) and Eli Lilly's tirzepatide (Zepbound, Mounjaro) have been recommended as first-line treatments for obesity by the European Association for the Study of Obesity. The guidelines emphasize their effectiveness in weight loss and managing obesity-related complications, while also acknowledging the need for comprehensive patient care and lifestyle strategies.
Oct 2, 2025
Uttar Pradesh leads in India's pharmaceutical market; Chief Minister emphasizes the importance of ensuring drug safety by pharmacists.
Uttar Pradesh Chief Minister Yogi Adityanath emphasized the importance of drug safety in the pharmaceutical sector during the Chemists and Druggists Federation's annual program. He highlighted the dangers posed by counterfeit medicines, urging chemists to take responsibility in safeguarding public health.
Oct 1, 2025
Transforming Patents into Patient Benefits: FDA Strategies to Safeguard and Accelerate Medical Advancements
A new white paper, "A Blueprint for FDA," by USC scholars recommends updates to FDA policies to enhance innovation and access to medicines. It emphasizes the need for streamlined approvals for generics and biosimilars, addressing concerns over Medicare's drug pricing rules, and balancing patent protections with affordable access. The report advocates for legislative changes to support timely patient access to treatments.
Oct 1, 2025
A biotech company is working to deliver RNA medications to the brain. | BioPharma Dive
Aerska, a Dublin-based biotech startup, has raised $21 million in seed funding to develop RNA interference therapies targeting brain diseases. Co-led by Age1 and Backed VC, the company aims to overcome the blood-brain barrier using its "antibody-oligo conjugate" platform. Aerska's focus includes genetic forms of Alzheimer’s and Parkinson’s diseases, positioning it as a leader in CNS therapeutics.
Oct 1, 2025
Is There New Promise for Psychedelic Drug Therapies? | Haynes Boone - JDSupra
Renewed interest in psychedelics for treating conditions like depression and PTSD has led to numerous patent applications for compounds such as psilocybin, LSD, and MDMA. Despite significant barriers due to their Schedule I status, the Johns Hopkins Center for Psychedelic and Consciousness Research has shown promising results. Regulatory changes may be on the horizon, with support from officials like HHS Secretary Robert F. Kennedy, Jr.
Oct 1, 2025
CDSCO provides clarification regarding the authorization of combination packs for specific injections, according to DrugsControl.
The Central Drug Standard Control Organization (CDSCO) has clarified the approval process for combi-packs of lyophilized dry powder for injection, specifically regarding intravenous sodium chloride injections. This clarification aligns with Rule 2(1)(w) of the New Drugs and Clinical Trials (NDCT) Rules 2019, addressing concerns about cocrystal supramolecular active pharmaceutical ingredients (APIs) and coformers.
Oct 1, 2025
Trump's drug tariff has currently exempted the majority of Chinese pharmaceutical companies, but more challenges could arise in the future.
Chinese pharmaceutical company Akeso's new cancer treatment, Ivonescimab, has outperformed Merck's Keytruda in clinical trials, with patients experiencing longer periods before tumor growth. Summit Therapeutics, which licensed Ivonescimab for commercialization, saw its shares rise. Despite regulatory risks from the U.S., the collaboration between Chinese and American biotech firms continues to thrive, driven by demand for innovative therapies.
Oct 1, 2025
Pfizer Secures Historic Deal with U.S. Government to Reduce Medication Prices for ...
Pfizer Inc. has reached a landmark agreement with the Trump Administration to reduce prescription drug costs for U.S. patients. This initiative aims to ensure lower prices for medications while enhancing America's position in biopharmaceutical innovation.
Oct 1, 2025
The potential for AI to spark new conflicts regarding pharmaceutical patents - STAT News
AI is reshaping the biotech patent landscape, raising questions about AI's role as an inventor and the knowledge expected from skilled professionals. DeAnn Smith, a biotech patent lawyer at Foley Hoag, anticipates future litigation will clarify these issues. The evolving nature of intellectual property in the age of AI presents significant challenges and opportunities for the industry.
Oct 1, 2025
Alteogen has achieved a significant milestone in its technology licensing agreement with an international pharmaceutical company.
Alteogen has achieved a significant milestone in its technology export contract with Merck (MSD) following the FDA's approval of MSD's anti-cancer drug "Keytruda" subcutaneous injection, utilizing Alteogen's ALT-B4 technology. Alteogen will receive $25 million in milestone payments, representing over 10% of its previous year's sales. The approval enhances patient treatment options by converting intravenous to subcutaneous administration.
Oct 1, 2025
A US judge rules that Biogen must pay Genentech $88 million in a dispute over an MS medication. - TradingView
A California federal judge ruled that Biogen must pay Roche's Genentech over $88 million in patent royalties for Tysabri, a drug for multiple sclerosis and Crohn's disease. The royalties are owed for Tysabri manufactured using Genentech's patents before their expiration in December 2018. Biogen earned over $1.7 billion from Tysabri sales last year.
Sep 30, 2025
Novo Nordisk Set to Introduce Ozempic in India Before Semaglutide Patent Expires in 2026
Novo Nordisk plans to launch its diabetes and weight management drug, Ozempic, in India ahead of the 2026 patent expiry for semaglutide, its active ingredient. This move is expected to stimulate competition as local manufacturers prepare to introduce generics, potentially lowering prices and increasing access to GLP-1 receptor agonists for managing type 2 diabetes and obesity.
Sep 30, 2025
Indian Pharmaceutical Companies Withdraw Medications in the US Due to Quality Issues
Several Indian pharmaceutical companies, including Glenmark, Granules India, Sun Pharma, Zydus, and Unichem, are recalling medicines from the US market due to quality flaws, as reported by the US Food and Drug Administration (FDA) on September 30, 2025.
Sep 30, 2025
Indian pharmaceutical companies poised to gain from $236 billion in drugs set to lose patent protection over the next five years.
The U.S. faces a significant 'patent cliff' from 2025-2029, with $236 billion in pharma revenue at risk as major drugs like Keytruda (Merck) and Perjeta (Genentech) lose exclusivity. This shift will boost generics and biosimilars, benefiting companies like Cipla and Sun Pharma, while challenging big pharma to adapt and innovate in a competitive landscape.
Sep 30, 2025
Leading Pharmaceuticals of the First Half of 2025 - Drug Discovery and Development
The pharmaceutical industry faces a shift as blockbuster drugs like Merck's Keytruda, projected to generate $15.2B in sales, approach patent expirations. With Medicare price setting starting in 2028, investor sentiment has cooled for GLP-1s from Lilly and Novo Nordisk. Meanwhile, AbbVie's Skyrizi shows strong growth. Companies must innovate rapidly to maintain market dominance amid changing dynamics.
Sep 30, 2025
Metsera's weight loss medication demonstrates promising mid-stage effectiveness, bolstering Pfizer's $4.9 billion investment.
Metsera's investigational GLP-1 therapy, MET-097i, demonstrated a 14% placebo-adjusted weight reduction in a mid-stage study, supporting Pfizer's $4.9 billion acquisition of Metsera. Analysts noted MET-097i's promising efficacy and tolerability compared to Eli Lilly's tirzepatide. Ongoing studies include combination therapies and an oral formulation, with further data expected by year-end.
Sep 30, 2025
Ozempic receives approval from CDSCO, Novo Nordisk prepares for upcoming launch in India | Company News
The Central Drugs Standard Control Organisation (CDSCO) has approved Novo Nordisk's diabetes drug Ozempic, a semaglutide-based solution, for the Indian market. This approval, granted on September 26, is anticipated to enhance the growing antiobesity market, valued at ₹752 crore, with semaglutide contributing ₹426 crore. A launch date for Ozempic is expected soon.
Sep 30, 2025
Expansion of the Blockbuster Pharmaceuticals Market Driven by Innovation, Biologics, and Specialized Treatments
The global blockbuster drugs market, valued at USD 357 billion in 2024, is projected to reach USD 627 billion by 2034, growing at a CAGR of 5.6%. Key drivers include rising chronic disease prevalence and demand for biologics and specialty drugs. Major players include Pfizer, Novartis, Roche, and Merck & Co., with oncology therapies leading sales.
Sep 30, 2025
Ozempic, the popular weight-loss medication, set to launch in India shortly: What is its effectiveness?
Novo Nordisk's Ozempic, a diabetes treatment known for its weight-loss benefits, has been approved for use in India. This once-a-week injection, containing semaglutide, helps manage blood sugar levels and promotes weight loss. The Indian anti-obesity drug market is growing rapidly, and Ozempic's launch is expected to enhance competition among weight-loss medications. Pricing details are yet to be announced.
Sep 30, 2025
Denmark lowers its GDP growth forecast due to challenges faced by major exporter Novo Nordisk.
Denmark's second-quarter GDP growth was revised down to 1% due to a slowdown in pharmaceutical exports, particularly from Novo Nordisk. The company, known for its diabetes and obesity drugs Ozempic and Wegovy, plans to cut 11% of its workforce amid declining sales and competition. Novo's shares fell over 3% in Copenhagen, reflecting a nearly 40% year-to-date decline.
Sep 30, 2025
Boryeong has begun to broaden its anticancer offerings through the acquisition of the global operations of the bloc.
Boryeong has announced the acquisition of global rights for the anticancer drug Taksotel for €175 million, expanding its portfolio after Gemza and Alimta. This move aims to enhance Boryeong's position in the global market, allowing direct distribution in 19 countries. The company plans to produce Taksotel at its Yesan Campus, strengthening its foothold in the anticancer drug sector.
Sep 30, 2025
Boryeong has obtained the rights to blockbuster anticancer medications valued at 2 trillion won.
Boryeong is exploring the acquisition of Sanofi's blockbuster anticancer drug, Taxotel, to enhance its LBA (Legacy Brands Acquisition) strategy, following previous acquisitions of Gemza and Alimita. This move aims to strengthen Boryeong's position in the global anticancer market, which already accounts for over 20% of its sales. The company is also preparing for potential growth in global CDMO services.
Sep 30, 2025
MDC requests clarification regarding the exemption application for nafithromycin from the DPCO.
The Multidisciplinary Committee of Experts (MDC) is seeking clarification on Wockhardt Ltd's application for exemption of nafithromycin tablets from pricing norms under the DPCO, 2013. Nafithromycin, India's first indigenous antibiotic, targets drug-resistant pneumonia and was launched on November 20, 2024. The committee noted discrepancies in patent documentation and directed further investigation before making a decision.
Sep 30, 2025
Factor Bioscience Files Lawsuit Against Cellectis and AstraZeneca for Alleged Gene-Editing Patent Violations
Factor Bioscience Inc. has filed a patent infringement complaint against Cellectis Inc., Cellectis SA, and AstraZeneca PLC, alleging unauthorized use of its TALEN gene editing technology. The lawsuit, filed in Delaware, claims Cellectis incorporated Factor's patented methods into its CAR-T programs without a license, impacting AstraZeneca's investments in Cellectis. Factor aims to protect its intellectual property rights.
Sep 30, 2025
Single-Page Overview" for Grasping Industrial Chains: Novel Pharmaceuticals and Licensing - 36氪
In 2025, China's innovative drug industry is poised for recovery, driven by supportive policies and a surge in overseas licensing, with upfront payments reaching $5.7 billion. Companies like BeiGene, with products like Zanubrutinib, are leading profitability. The market is expected to grow significantly, highlighting the shift towards global commercialization and diversified revenue sources for innovative drug enterprises.
Sep 30, 2025
Patents Maintain Elevated Drug Costs, While Transparency Efforts Challenge This - Legal Reader
A recent study highlights that disclosing clinical trial data can reduce low-value drug patents, improving patient access to affordable medications. Many patents are based on minor changes rather than true innovations, leading to higher costs. Transparency in the approval process is essential to ensure patents reward genuine advancements, benefiting patients and health systems alike.
Sep 30, 2025
Could the Upcoming Patent Expiration Wave Increase M&A Activity, and What Are the Implications for ... - JD Supra
Experts predict a surge in merger and acquisition (M&A) activity in the pharmaceutical industry, driven by a looming patent cliff expected to risk $180 billion to $400 billion in revenue by 2030. Major drugs like Keytruda, Opdivo, and Eliquis will lose patent protection, prompting companies to acquire biotech firms to offset revenue losses and innovate.
Sep 30, 2025
Europe's Biosimilars Market Projected to Grow at a CAGR of 15.4% - openPR.com
The Europe biosimilars market is projected to grow at a CAGR of 15.4%, expanding from USD 12.3 billion in 2024 to USD 33.5 billion by 2031. This growth is driven by the expiration of biologic patents, rising healthcare costs, and increased regulatory support from the European Medicines Agency (EMA). Key players include Sandoz AG, Amgen Inc., and Pfizer Inc.
Sep 30, 2025
Pharmaceutical Companies Turn to China Amid Patent Expiration as EquitiesFirst Facilitates Capital Access | Outlook India
Hong Kong's biotech index has soared nearly 80% in 2025, outpacing the Hang Seng Index, as mainland Chinese investors inject around $90 billion into the sector. This surge indicates a major shift, with Chinese companies now accounting for one-third of global pharmaceutical licensing deals, a significant increase from previous years.
Sep 30, 2025
How Trump's drug pricing strategy for October could provide relief for families - NewsBreak
Health and Human Services Secretary Robert F. Kennedy Jr. is set to unveil a proposal on Oct. 12 aimed at reducing high drug costs, which have risen significantly faster than inflation. The plan focuses on expediting the approval of generic drugs and biosimilars to enhance competition and lower prices, addressing issues like patent manipulation that hinder market access.
Sep 29, 2025
Walmsley's Ideal Recruitment Must Urgently Discover Some Game-Changing Medications
Luke Miels has been appointed as the new CEO of GSK Plc, succeeding Emma Walmsley, who has led the company for nearly nine years. Miels, who joined GSK in 2017, will take over at the start of next year, with a focus on developing more blockbuster drugs from GSK's laboratories.
Sep 29, 2025
Pharmaceutical companies in Telangana concerned about effects of US tariffs
Telangana's pharmaceutical industry is cautiously navigating the US's 100% tariffs on branded drugs, focusing on trade negotiations and diversifying markets. While local firms like Dr Reddy's Laboratories and Aurobindo Pharma remain largely insulated due to their generics focus, concerns grow over potential future tariff expansions. The state contributes significantly to India's pharma exports, with 32% directed to the US.
Sep 29, 2025
Transforming Patents into Patient Benefits: FDA Strategies to Safeguard and Accelerate Medical Advancements
A new white paper, "FDA Blueprint," by USC scholars recommends updates to FDA policies to enhance innovation and access to medicines. It emphasizes the need for streamlined approvals for generics and biosimilars, particularly in light of Medicare's drug pricing rules. The paper advocates for balancing patent protections with timely access to affordable treatments, ensuring that innovation continues to thrive.
Sep 29, 2025
Trump's Proposed Full Drug Tariff May Harm U.S. Consumers More Than Pharmaceutical Companies
Trump's proposed 100% drug tariff on imported medications is expected to significantly increase costs for American consumers, according to economist Justin Wolfers. The tariffs will not pressure foreign pharmaceutical companies to lower prices, as patented drugs lack competition. Consequently, American patients and insurers will bear the financial burden, potentially forcing them to choose between medications and essential expenses.
Sep 29, 2025
Axsome Files Lawsuit Against Apotex to Prevent Generic Versions of Symbravo Migraine Medication - Bloomberg Law News
Axsome Therapeutics Inc. has filed a patent lawsuit against Apotex Inc., claiming that its proposed generic copies of the migraine drug Symbravo infringe 75 patents. The complaint, filed on September 26, alleges that Apotex's tablets, which contain meloxicam and rizatriptan, violate patents related to the drug's composition and use for treating acute migraines.
Sep 29, 2025
Health Canada's plan to simplify the approval process could speed up legal disputes over biosimilar patents.
Health Canada has proposed a significant change to biosimilar drug regulations, potentially eliminating the requirement for phase 3 clinical trials for market entry. This move may accelerate biosimilar submissions and patent litigation in Canada, aligning with similar actions in the UK and EU. The draft guidance aims to streamline the approval process while still ensuring safety and immunogenicity data is collected.
Sep 29, 2025
Pharma Update: Drug Pricing Issues Impact Accessibility, Concerns Grow Over Pediatric Flu Vaccination Rates
The Trump administration plans to impose a 100% tariff on branded drugs imported into the US starting Oct. 1, raising concerns about patient costs and supply chain disruptions. Additionally, new research links pediatric influenza to neurological complications, highlighting vaccination gaps. AbbVie has submitted a new drug application for tavapadon, a therapy for Parkinson’s disease, targeting improved motor function.
Sep 29, 2025
On the 29th, Alteogen revealed that it has chosen Korea Investment & Securities as the organizer.
Alteogen has appointed Korea Investment & Securities to facilitate its relocation to KOSPI, following its listing plan disclosed in August. CEO Park Soon-jae highlighted the stable sales from Keytruda Curex, approved by the FDA, as a foundation for increasing shareholder value. The company is also advancing its pipeline, including ALT-B4, in collaboration with major firms like Merck and AstraZeneca.
Sep 29, 2025
Trump's Tariffs Could Impact Drug Costs and the Global Pharmaceutical Industry - Grand Pinnacle Tribune
President Trump announced a 100% tariff on imported branded drugs starting October 1, 2025, aiming to boost US pharmaceutical manufacturing. This move could impact $220 billion in imports and raise average tariff rates by 3.3%. Major companies like Novartis AG, Sanofi SA, and Merck & Co. are responding by investing in US facilities, while the announcement has caused global pharmaceutical stocks to plummet.
Sep 29, 2025
With the surge in mergers and acquisitions related to obesity, pharmaceutical companies may become overwhelmed by the potential prospects. | PharmaVoice
The GLP-1 drug market is booming, with companies pursuing next-generation products despite recent setbacks like Pfizer's danuglipron. Key players include Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Upcoming innovations focus on patient-friendly delivery methods, such as oral semaglutide. Pfizer's acquisition of Metsera highlights the trend, while Roche's $2.7 billion deal for combination drugs underscores the competitive landscape.
Sep 29, 2025
Ozempic receives approval in India; Novo Nordisk India's leader describes it as 'essential' - India Today
Novo Nordisk is set to launch Ozempic (semaglutide) in India, enhancing treatment options for Type 2 diabetes and obesity. The once-weekly injectable, approved by the US FDA in 2017, is expected to complete Novo Nordisk's semaglutide portfolio. The World Health Organization's inclusion of Ozempic as an essential medicine underscores its significance for patients.
Sep 29, 2025
Reasons Why Pfizer's Outlook After COVID Appears More Promising Than Before
Pfizer's COVID-19 product sales have plummeted, with Comirnaty and Paxlovid generating only $945 million and $918 million, respectively, in the first half of 2025. However, the company is optimistic about its future, driven by cancer treatments acquired from Seagen, particularly Padcev, which saw a 38% sales increase. Elrexfio also shows promise for multiple myeloma treatment.
Sep 29, 2025
Trump imposes full 100% tariff on pharmaceuticals, but Eli Lilly is exempt - IndyStar
President Trump announced a 100% tariff on branded pharmaceutical products entering the U.S. starting Oct 1, but Eli Lilly is exempt due to its commitment to building production plants in the country. The exemption aims to encourage domestic manufacturing among drugmakers.
Sep 29, 2025
Walmsley's Ideal Recruitment is in Urgent Need of Major Pharmaceutical Breakthroughs - Mint
GSK Plc has appointed Luke Miels as CEO, succeeding Emma Walmsley, who led the company for nearly nine years. Miels, previously chief commercial officer, faces challenges in delivering blockbuster drugs and improving share prices. Analysts believe he is well-positioned to achieve GSK's 2031 sales target of over £40 billion, despite concerns about the drug pipeline's late-stage results.
Sep 29, 2025
Could the Upcoming Patent Expiration Wave Increase M&A Activity, and What Are the Implications for ...
Experts predict a surge in merger and acquisition (M&A) activity in the pharmaceutical industry, driven by a looming patent cliff that could risk $180 billion to $400 billion in revenue by 2030. Major drugs like Keytruda, Opdivo, and Eliquis will lose patent protection, prompting companies to acquire biotech firms to offset revenue losses and innovate.
Sep 29, 2025
Genmab to Acquire Merus' Head and Neck Cancer Treatment for $8 Billion, Anticipating Major Market Success
Genmab has announced an $8 billion acquisition of Merus, paying $97 per share, to enhance its pipeline with the late-stage drug candidate petosemtamab (peto) for head and neck cancer. Peto, a bispecific antibody targeting EGFR and LGR5, shows promise with a 60% response rate in trials. The deal is expected to close in early 2026, funded by cash and new debt.
Sep 29, 2025
AbbVie Requests FDA Approval for Tavapadon as a Treatment for Parkinson's Disease - TradingView
AbbVie (ABBV) has submitted an FDA filing for its investigational drug tavapadon, aimed at treating Parkinson’s disease. Supported by three late-stage studies, tavapadon showed significant symptomatic improvement. If approved, it would be AbbVie’s second recent FDA clearance in this area, following the approval of Vyalev. AbbVie continues to expand its neuroscience portfolio, despite setbacks with other drugs.
Sep 29, 2025
ME Therapeutics Obtains U.S. Patent for Primary Candidate and Expands Further...
ME Therapeutics Holdings Inc. has secured a U.S. patent for its lead G-CSF antibody candidate, H1B11-12, aimed at cancer treatment. The company is advancing its immuno-oncology drug development, including therapeutic mRNA and in vivo CAR programs. CEO Salim Dhanji highlighted key milestones, including cell line development and preclinical testing, as ME Therapeutics expands its research team.
Sep 29, 2025
In August, 15 states and five Union Territories failed to provide NSQ data, according to DrugsControl Media Services.
The Central Drugs Standard Control Organisation (CDSCO) reported 94 Not of Standard Quality (NSQ) drug samples in August, with 65% identified by state drug regulators. However, 15 states and five Union Territories (UTs) failed to submit NSQ data during this period.
Sep 29, 2025
India requires hospitals to implement drug reaction reporting forms to improve patient safety.
India's Union government will require all hospitals to implement an Adverse Drug Reaction (ADR) reporting form during patient admissions to improve patient safety. This policy change aims to enhance monitoring and response to drug-related side effects, ensuring better healthcare outcomes.
Sep 28, 2025
Why Pfizer's Prospects After COVID Appear More Promising Than Ever - The Globe and Mail
Pfizer's COVID-19 product sales have plummeted, with Comirnaty and Paxlovid generating only $945 million and $918 million, respectively, in the first half of 2025. However, the company is optimistic about its future, driven by cancer treatments acquired from Seagen, particularly Padcev, which saw a 38% sales increase. Elrexfio also shows promise in treating multiple myeloma.
